Fig. 2
The effects of granulocyte depletion on BsAb directed T cell trafficking and in vivo anti-tumor response. A Luciferase transduced T cells [Luc(+) T cells] were administered with GD2-BsAb and anti-GR1 or anti-Ly6G antibody to treat small cell lung cancer cell line (NCI-N417) xenografts. Luc(+) T cells were administered intravenously (iv) on day 0, and GD2-BsAbs were iv administered on day 0 and day 5 separately. Anti-Ly6G or anti-GR1 antibodies were administered on day -1 and day 4 intraperitoneally. B Bioluminescence of Luc(+) T cells infiltrated into tumors were monitored. The bioluminescence images on day 4 and quantification of the bioluminescence in the lesions of tumor. Control BsAb, Luc(+) T cells plus control BsAb; GD2-BsAb, Luc(+) T cells plus GD2-BsAb; GD2-BsAb plus anti-GR1, Luc(+) T cells plus GD2-BsAb plus anti-GR1 antibody; GD2-BsAb plus anti-Ly6G, Luc(+) T cells plus GD2-BsAb plus anti-Ly6G antibody. C In vivo anti-tumor response by GD2-BsAb and granulocyte depleting antibodies was tested against melanoma cell line (M14) xenografts. Control BsAb, Luc(+) T cells plus control BsAb; GD2-BsAb, Luc(+) T cells plus GD2-BsAb; GD2-BsAb+ anti-GR1, Luc(+) T cells plus GD2-BsAb plus anti-GR1 antibody; GD2-BsAb+ anti-Ly6G, Luc(+) T cells plus GD2-BsAb plus anti-Ly6G antibody. D In vivo anti-tumor effect of GD2-EATs with anti-Ly6G antibody was tested against neuroblastoma patient-derived xenografts (PDXs), and long-term survival was analyzed